Company: AEMD
Filing Date: 2025-06-26
Form Type: 10-K
Source: 0001683168-25-004780
Chunk: 947

Company: AETHLON MEDICAL INC
Filing Date: 2025-06-26
Form: 10-K
Item: Item 6
Chunk 947
---
 each granted an RSU in the amount of 17,858
shares under the 2020 Plan. The RSUs are subject to vesting in four equal installments, with 25% of the restricted stock units vesting
on each of June 30, 2025, September 30, 2025, December 31, 2025, and March 31, 2026, subject in each case to the director’s Continuous
Service (as defined in the 2020 Plan), through such dates. Vesting will terminate upon the director’s termination of Continuous
Service prior to any vesting date.

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable to a “smaller
reporting company” as defined under Item 10(f)(1) of Regulation S-K of the Securities Act.

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

    Pages
  
    Report of Independent Registered Public Accounting Firm (Haskell & White, LLP, San Diego, CA PCAOB ID No. 200)
    F-2
  
    Report of Independent Registered Public Accounting Firm (Baker Tilly
    US, LLP, San Diego, CA PCAOB ID No. 23)
    F-4
  
    Consolidated Balance Sheets
    F-5
  
    Consolidated Statements of Operations
    F-6
  
    Consolidated Statements of Equity
    F-7
  
    Consolidated Statements of Cash Flows
    F-8
  
    Notes to Consolidated Financial Statements
    F-9

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS
ON ACCOUNTING AND FINANCIAL DISCLOSURE

None.

 59 

ITEM 9A. CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

We maintain “disclosure
controls and procedures” (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) that are designed to ensure that information
required to be disclosed, in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods specified
in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Interim
Chief Executive Officer and Chief Financial Officer (who is our principal executive officer and principal financial officer), to allow
timely decisions regarding required disclosures.

In designing and evaluating
the